NCT05753215 - Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Bone InfectionJoint InfectionBone and Joint Infection

Interventions

DRUG

Omadacycline Pill

Omadacycline will be administered 300 mg orally daily without the loading dose.

DRUG

Standard of Care

Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.

Trial Locations (1)

RECRUITING

The Lundquist Institute For Biomedical Innovation at Harbor-UCLA Medical Center, Torrance